Suppr超能文献

米替福新对一组唑类和棘白菌素耐药菌株的体外抗真菌药敏谱

In Vitro Antifungal Susceptibility Profile of Miltefosine against a Collection of Azole and Echinocandins Resistant Strains.

作者信息

Nosratabadi Mohsen, Akhtari Javad, Faeli Leila, Haghani Iman, Aghili Seyed Reza, Shokohi Tahereh, Hedayati Mohammad Taghi, Zarrinfar Hossein, Mohammadi Rasoul, Najafzadeh Mohammad Javad, Khodavaisy Sadegh, Al-Harrasi Ahmed, Javan-Nikkhah Mohammad, Kachuei Reza, Salimi Maryam, Fattahi Mahsa, Badali Hamid, Al Hatmi Abdullah M S, Abastabar Mahdi

机构信息

Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari 4816983663, Iran.

Invasive Fungi Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari 4816983663, Iran.

出版信息

J Fungi (Basel). 2022 Jul 4;8(7):709. doi: 10.3390/jof8070709.

Abstract

species are filamentous fungi that cause a variety of infections in humans. Because they are commonly resistant to many antifungal drugs currently available in clinical settings, research into alternative targets in fungal cells and therapeutic approaches is required. The antifungal activity of miltefosine and four comparators, amphotericin B, voriconazole, itraconazole, and caspofungin, were tested in vitro against a collection of susceptible and resistant clinical ( = 68) and environmental ( = 42) isolates. Amphotericin B (0.8 μg/mL) had the lowest geometric mean (GM) MICs/MECs values followed by miltefosine (1.44 μg/mL), voriconazole (2.15 μg/mL), caspofungin (7.23 μg/mL), and itraconazole (14.19 μg/mL). Miltefosine was the most effective agent against isolates after amphotericin B indicating that miltefosine has the potential to be studied as a novel treatment for infections.

摘要

该菌种是丝状真菌,可导致人类多种感染。由于它们通常对临床环境中目前可用的许多抗真菌药物具有抗性,因此需要对真菌细胞中的替代靶点和治疗方法进行研究。在体外测试了米替福新和四种对照药物两性霉素B、伏立康唑、伊曲康唑和卡泊芬净对一组敏感和耐药的临床(n = 68)和环境(n = 42)分离株的抗真菌活性。两性霉素B(0.8μg/mL)的几何平均(GM)最低抑菌浓度/最低有效浓度值,其次是米替福新(1.44μg/mL)、伏立康唑(2.15μg/mL)、卡泊芬净(7.23μg/mL)和伊曲康唑(14.19μg/mL)。米替福新是仅次于两性霉素B的对分离株最有效的药物,这表明米替福新有潜力作为一种新型治疗方法用于该菌种感染的研究。

相似文献

本文引用的文献

6
Phylogenetic Analysis of Clinically Relevant Fusarium Species in Iran.伊朗临床相关镰刀菌属物种的系统发育分析。
Mycopathologia. 2020 Jun;185(3):515-525. doi: 10.1007/s11046-020-00460-x. Epub 2020 Jun 6.
7
Human fusariosis: An emerging infection that is difficult to treat.人类镰刀菌病:一种难以治疗的新兴感染。
Rev Soc Bras Med Trop. 2020;53:e20200013. doi: 10.1590/0037-8682-0013-2020. Epub 2020 Jun 1.
8
Pathogenomics and Management of Diseases in Plants.植物病害的病原基因组学与管理
Pathogens. 2020 May 1;9(5):340. doi: 10.3390/pathogens9050340.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验